Business

Spanish pharmaceutical company Almirall has issued a statement saying that the company will “reorganize” its European operations as a result of “economic driven decisions, made by country’s health authorities that have negatively affected the growth… Read more . . .

According to Bespak parent company Consort Medical, Bespak will construct a new dedicated facility at it’s King’s Lynn, UK site in order to meet production demands after signing a contract to manufacture a proprietary dry… Read more . . .

Imperial Innovations Group has announced that it is contributing £4.25 million towards a total of £17 million ($27.5 million) in funding for a new inhaled drug discovery and development company called Pulmocide. Other investors in… Read more . . .

Particle Sciences has announced that it has been awarded a contract for development of an intranasal progesterone formulation for the treatment of traumatic brain injury by BHR Pharma, a subsidiary of Besins Healthcare. Besins announced… Read more . . .

The United States Patent and Trademark Office (USPTO) has issued Civitas Therapeutics US Patent No. 8,545,878, with an expiration date of November 16, 2032, for a patent titled “Capsules containing high doses of levodopa for… Read more . . .

Novartis has announced that “it will initiate consultation on proposals to close” its respiratory R&D center in Horsham, UK. According to Novartis, the potential closing will affect “up to 371 roles” at the site, plus… Read more . . .

GlaxoSmithKline and Theravance have announced the availability of the Breo Ellipta fluticasone furoate/vilanterol DPI in the US. The FDA approved Breo Ellipta for the treatment of COPD in May 2013. The launch triggers a $30… Read more . . .

Depomed has announced a new launch of Lazanda fentanyl nasal spray in the US for the management of breakthrough pain in cancer patients who get inadequate relief from opioids. The company acquired the product from… Read more . . .

Alexza Pharmaceuticals and Grupo Ferrer have launched Adasuve loxapine inhalation powder for the treatment of agitation in schizophrenic patients in Austria, the companies said. Ferrer is working with Vienna-based AOP Orphan Pharmaceuticals to commercialize Adasuve… Read more . . .